United States, Dec. 3 -- The U.S. Food and Drug Administration granted approval for Avance (acellular nerve allograft-arwx) in surgical implantation. Avance is a peripheral nerve scaffold approved for sensory nerve discontinuities (?25mm) (breaks in the pathway of sensory nerves) in adults and pediatric patients aged one month and older. Under the Accelerated Approval pathway, Avance is also approved for larger sensory nerve discontinuities (>25mm), motor and mixed nerve discontinuities.Avance was studied in patients with sensory nerve discontinuities and additional investigations of mixed and motor nerve discontinuities. Unlike some current treatments that require surgeons to remove healthy nerve tissue from another part of the patient's b...